ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis - GlobeNewswire

ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis  GlobeNewswire

Comments

Popular posts from this blog

What is Noma (Cancrum oris)? - News-Medical.Net

Urinary Tract Infection (UTI): Causes, Symptoms & Treatment - Cleveland Clinic